BiotechTube
Sulfateq

Sulfateq

Leiden, Netherlands· Est.
sulfateqbv.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Sulfateq is an innovative Dutch biotech leveraging insights from natural mitochondrial stress responses, such as hibernation, to develop novel small molecule therapies. Its lead programs target major chronic diseases including Parkinson's, diabetic kidney disease, COPD, and heart failure, with its most advanced asset, SUL-238, having a Phase II trial initiated by a partner. The company operates with a lean, experienced leadership team and a partnership-driven model to advance its pipeline of orally bioavailable compounds. Sulfateq's technology platform utilizes phenotypic screening to identify compounds that enhance mitochondrial function, addressing a significant unmet medical need in diseases of aging and metabolism.

NeurodegenerationChronic Kidney DiseaseCardiovascular DiseasePulmonary Disease

Technology Platform

Phenotypic screening platform inspired by natural mitochondrial stress responses (e.g., hibernation) to discover small molecules that improve mitochondrial respiration (ATP production), mitigate damage, and reduce oxidative stress.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The company addresses massive, underserved markets in chronic diseases (kidney, heart, lung, neurodegeneration) where mitochondrial dysfunction is a key driver.
A successful Phase II trial for SUL-238 in Parkinson's would validate the entire platform, creating significant partnering and financing opportunities across multiple indications.
The oral bioavailability of its compounds is a major advantage for chronic treatment regimens.

Risk Factors

High scientific risk as the novel mitochondrial-focused mechanism is unproven in human diseases.
As a small, private, pre-revenue company, it faces significant funding and resource constraints.
Heavy reliance on partners for clinical development and future commercialization dilutes control and economic upside.

Competitive Landscape

The field of mitochondrial therapeutics is emerging but competitive, with several biotechs and academic groups exploring various approaches (e.g., mitophagy inducers, metabolic modulators). Sulfateq's differentiation lies in its hibernation-inspired phenotypic screening platform. It faces competition from both niche mitochondrial-focused firms and large pharma companies with significant resources to enter the space.

More companies in Small Molecule Drugs →More companies in Netherlands →